Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative anlotinib-based therapy for muscle-invasive urothelial carcinoma
ChiCTR2200063085Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib, gemcitabine, cisplatin and penpulimab in transitional cell carcinoma (TCC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
anlotinibgemcitabinecisplatinpenpulimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2200063085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063085.